...
首页> 外文期刊>European journal of heart failure: journal of the Working Group on Heart Failure of the European Society of Cardiology >Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids.
【24h】

Left ventricular systolic dysfunction, total mortality, and sudden death in patients with myocardial infarction treated with n-3 polyunsaturated fatty acids.

机译:用n-3多不饱和脂肪酸治疗的心肌梗死患者的左心室收缩功能障碍,总死亡率和猝死。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

BACKGROUND: Sudden death (SD) has a major impact on mortality (M) in patients with left ventricular systolic dysfunction (SyD). In GISSI-Prevenzione, treatment with n-3 polyunsaturated fatty acids (PUFA) reduced M and SD in post-MI patients, but their effect in patients with SyD is unknown. METHODS: 11,323 patients with prior MI and NYHA class50%, SyD patients had higher M (12.3% vs. 6.0%) and SD (3.4% vs. 1.4%) rates. PUFA reduced M similarly in patients with (RR 0.76 (0.60-0.96) P=0.02) and without SyD (RR 0.81 (0.59-1.10) P=0.17) (heterogeneity tests P=0.55). In contrast, the effect on SD was markedly asymmetrical: PUFA produced a marked reduction (RR 0.42 (0.26-0.67) P=0.0003) of risk in SyD patients whereas the effect was less evident (RR 0.89 (0.41-1.69) P=0.71) in patients with EF>50% (heterogeneity tests P=0.07). There was a significant increase in SD with worsening EF (P test for trend=0.02), the benefit on SD in patients with EF50%. CONCLUSIONS: Increasing SyD is associated with elevated risk of SD and with increasing benefit from PUFA. The effect of PUFA on SD reduction was greater in patients with SyD. Prospective trials testing the effect of PUFA in populations with SyD are required.
机译:背景:猝死(SD)对左心室收缩功能障碍(SyD)患者的死亡率(M)具有重大影响。在GISSI-Prevenzione中,用n-3多不饱和脂肪酸(PUFA)治疗可降低MI后患者的M和SD,但尚不清楚它们在SyD患者中的作用。方法:招募了11,323名先前患有MI和NYHA II级的患者。在排除无射血分数(EF)测量的患者(1684)和数据缺失的患者(n = 9)之后,有9630名患者可供分析。拟合多元Cox回归调整的模型。结果:与EF> 50%的患者相比,SyD患者的M(12.3%vs. 6.0%)和SD(3.4%vs. 1.4%)患病率更高。在(RR 0.76(0.60-0.96)P = 0.02)和没有SyD(RR 0.81(0.59-1.10)P = 0.17)的患者中,PUFA相似地降低M(异质性检验P = 0.55)。相反,对SD的影响明显不对称:PUFA显着降低了SyD患者的风险(RR 0.42(0.26-0.67)P = 0.0003),而效果却不那么明显(RR 0.89(0.41-1.69)P = 0.71) )> EF> 50%的患者(异质性检验P = 0.07)。 EF恶化时,SD显着增加(趋势检验为P检验= 0.02),EF <= 40%的患者对SD的获益比EF> 50%的患者高4倍。结论:SyD的增加与SD风险增加和PUFA获益增加有关。 SyD患者中PUFA对SD降低的作用更大。需要前瞻性试验来测试PUFA对SyD人群的影响。

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号